All News

Kevin Day, PharmD, provides insight into his role in the Pharmacist Quality Rewards Program and what it’s doing for patients in his community.

The FDA expands Auvelity for Alzheimer-related agitation, offering a first nonantipsychotic option backed by trials.

Utilizing colleges and schools of pharmacy, researchers explorensolutions to the growing challenges affecting community pharmacy.

Drug pricing rules reshape pharmacy and manufacturer strategies, as transparency grows and 340B reforms intensify scrutiny.

Among community pharmacies and their patients, researchers explore the power of protected learning time for improving services and outcomes.

With its capabilities improving rapidly in the health care space, technology and pharmacy experts discuss AI’s future place in pharmacy practice as further developments are released.

Specialty pharmacy shifts toward holistic, empathetic care, easier oral therapies, and wider community access to advanced cell and gene treatments.

Pharmacy leaders face rapid change, which can boost agility and automate repetitive tasks.

These discussions focused on gaps in artificial intelligence, community-based advanced therapy, and demands of federal drug price negotiations.

An exploration of community pharmacists’ perceptions of e-pharmacy, assessing whether they believe it’s a threat or benefit.

FDA approves Caplyta to prevent schizophrenia relapse, cutting risk 63% with a stable metabolic profile.

Community pharmacists can help manage worsening wounds, coordinate rural care teams, and overcome time and scope limits to improve healing.

Pharmacies can use technology and artificial intelligence to cut specialty drug complexity, boost access and adherence, and help pharmacists guide patients.

Digital specialty pharmacy, AI-driven intent, and mega-blockbuster drugs reshape patient engagement, access, and long-term adherence strategies.

In adult patients at least 50 years old, researchers estimated lifetime costs and health outcomes of the 23-valent pneumococcal polysaccharide vaccine.

In part 2 of our World Immunization Week interview with Nathan Ott, PharmD, he discusses the power of collaboration and continuing education in boosting vaccine awareness.

Pharmacy benefit manager reforms, gene therapy scale-up, artificial trust risks, and more reshape specialty pharmacy.

Real-time prescription pricing and auto-applied discounts cut pharmacy counter surprises, speed therapy, and free pharmacists for patient-focused care.

In this episode, host Taylor Watterson, PharmD, PhD, brings us a solo rendition breaking down some of her recent research with SCRPTS Laboratory.

Lower patient caps shift costs to community pharmacies, fueling pharmacy benefit manager fees, mail-order growth, and pharmacy deserts.

The adeno-associated virus (AAV) vector-based gene therapy lunsotogene parvec-cwha received approval through the FDA Commissioner’s National Priority Voucher pilot program.

The drug’s indication for uncontrolled chronic spontaneous urticaria is the first biologic medicine of its kind, specifically explored amongst children 2 to 11 years old.

Pharmacists can review medications that delay wound healing, helping patients choose safer care and avoid infections.

As the “peptide craze” fuels a surge in unregulated vendors, pharmacists must serve as critical navigators to steer patients toward safe, pharmaceutical-grade alternatives.

GSK’s investigational drug for liver treatment was given fast-track designations to improve access in what the FDA considers a significant unmet medical need.

Nathan Ott, PharmD, discusses the evolution of pharmacists’ role in vaccine administration and how that role has changed since the COVID-19 pandemic and prior.

Following an FDA announcement on its deeper look into peptide restrictions, Christopher Shade, PhD, joined to provide insights on their functions for metabolic health and more.